The National Institutes of Health (NIH) is launching a program that will shepherd drug candidates aimed at treating rare and neglected diseases through the most challenging phase of drug development.
The program, called Therapeutics for Rare and Neglected Diseases (TRND), marks the agency's largest foray into developing drugs. It will bring together expertise from various sectors of the NIH—including the Office of Rare Diseases Research (ORDR), the National Human Genome Research Institute, and the NIH Chemical Genomics Center (NCGC)—as well as expertise from outside researchers and organizations. TRND's focus will be moving candidate molecules through the preclinical phase of development and then licensing the candidates to other entities for further development.
Kuehn BM. NIH Program to Boost Pipeline for Drugs to Treat Rare and Neglected Diseases. JAMA. 2009;302(2):133-134. doi:10.1001/jama.2009.940